Cargando…
Thromboembolic Antiphospholipid Syndrome (APS): Efficacy and Safety of Different Anticoagulants-Results of the APSantiCO Registry
Background: The particular challenge in dealing with patients with thromboembolic antiphospholipid syndrome (APS) is to establish an adequate therapy regime, as patients suffer from an increased risk of relapse despite antithrombotic treatment (ATT). Vitamin K antagonists (VKA) are the standard medi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409774/ https://www.ncbi.nlm.nih.gov/pubmed/36013082 http://dx.doi.org/10.3390/jcm11164845 |
_version_ | 1784774933261320192 |
---|---|
author | Schulz, Annabel Herrmann, Eva Ott, Olivia Lindhoff-Last, Edelgard |
author_facet | Schulz, Annabel Herrmann, Eva Ott, Olivia Lindhoff-Last, Edelgard |
author_sort | Schulz, Annabel |
collection | PubMed |
description | Background: The particular challenge in dealing with patients with thromboembolic antiphospholipid syndrome (APS) is to establish an adequate therapy regime, as patients suffer from an increased risk of relapse despite antithrombotic treatment (ATT). Vitamin K antagonists (VKA) are the standard medication of choice. The current data on the use of direct oral anticoagulants (DOAC) in APS patients remain limited. Methods: The results of the retrospective APSantiCO registry are presented. In 80 patients with APS, the efficacy and safety of different ATT regimens were analyzed. Results: At the time of inclusion, 43.8% of patients were treated with VKA and 36.3% with DOAC. Medication regimes changed several times and 279 treatment phases were further analyzed with a total treatment length of 7529 months. The incidence of recurrent arterial thrombosis was significantly larger in the DOAC group compared with the VKA group (p < 0.001), while the incidence of recurrent venous thrombosis was comparable between both groups, as was the incidence of bleedings. Heavy menstrual bleeding was the most frequently observed bleeding complication. Conclusions: The data suggest that DOAC may be an alternative to VKA for APS patients with venous thromboembolism, while VKA should be used in APS-related arterial thrombosis. |
format | Online Article Text |
id | pubmed-9409774 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94097742022-08-26 Thromboembolic Antiphospholipid Syndrome (APS): Efficacy and Safety of Different Anticoagulants-Results of the APSantiCO Registry Schulz, Annabel Herrmann, Eva Ott, Olivia Lindhoff-Last, Edelgard J Clin Med Article Background: The particular challenge in dealing with patients with thromboembolic antiphospholipid syndrome (APS) is to establish an adequate therapy regime, as patients suffer from an increased risk of relapse despite antithrombotic treatment (ATT). Vitamin K antagonists (VKA) are the standard medication of choice. The current data on the use of direct oral anticoagulants (DOAC) in APS patients remain limited. Methods: The results of the retrospective APSantiCO registry are presented. In 80 patients with APS, the efficacy and safety of different ATT regimens were analyzed. Results: At the time of inclusion, 43.8% of patients were treated with VKA and 36.3% with DOAC. Medication regimes changed several times and 279 treatment phases were further analyzed with a total treatment length of 7529 months. The incidence of recurrent arterial thrombosis was significantly larger in the DOAC group compared with the VKA group (p < 0.001), while the incidence of recurrent venous thrombosis was comparable between both groups, as was the incidence of bleedings. Heavy menstrual bleeding was the most frequently observed bleeding complication. Conclusions: The data suggest that DOAC may be an alternative to VKA for APS patients with venous thromboembolism, while VKA should be used in APS-related arterial thrombosis. MDPI 2022-08-18 /pmc/articles/PMC9409774/ /pubmed/36013082 http://dx.doi.org/10.3390/jcm11164845 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Schulz, Annabel Herrmann, Eva Ott, Olivia Lindhoff-Last, Edelgard Thromboembolic Antiphospholipid Syndrome (APS): Efficacy and Safety of Different Anticoagulants-Results of the APSantiCO Registry |
title | Thromboembolic Antiphospholipid Syndrome (APS): Efficacy and Safety of Different Anticoagulants-Results of the APSantiCO Registry |
title_full | Thromboembolic Antiphospholipid Syndrome (APS): Efficacy and Safety of Different Anticoagulants-Results of the APSantiCO Registry |
title_fullStr | Thromboembolic Antiphospholipid Syndrome (APS): Efficacy and Safety of Different Anticoagulants-Results of the APSantiCO Registry |
title_full_unstemmed | Thromboembolic Antiphospholipid Syndrome (APS): Efficacy and Safety of Different Anticoagulants-Results of the APSantiCO Registry |
title_short | Thromboembolic Antiphospholipid Syndrome (APS): Efficacy and Safety of Different Anticoagulants-Results of the APSantiCO Registry |
title_sort | thromboembolic antiphospholipid syndrome (aps): efficacy and safety of different anticoagulants-results of the apsantico registry |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409774/ https://www.ncbi.nlm.nih.gov/pubmed/36013082 http://dx.doi.org/10.3390/jcm11164845 |
work_keys_str_mv | AT schulzannabel thromboembolicantiphospholipidsyndromeapsefficacyandsafetyofdifferentanticoagulantsresultsoftheapsanticoregistry AT herrmanneva thromboembolicantiphospholipidsyndromeapsefficacyandsafetyofdifferentanticoagulantsresultsoftheapsanticoregistry AT ottolivia thromboembolicantiphospholipidsyndromeapsefficacyandsafetyofdifferentanticoagulantsresultsoftheapsanticoregistry AT lindhofflastedelgard thromboembolicantiphospholipidsyndromeapsefficacyandsafetyofdifferentanticoagulantsresultsoftheapsanticoregistry |